- Home
- LXEH vs SCYX Comparison
LXEH vs SCYX Comparison
Compare LXEH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- SCYX
- Stock Information
- Founded
- LXEH 2001
- SCYX 1999
- Country
- LXEH China
- SCYX United States
- Employees
- LXEH N/A
- SCYX N/A
- Industry
- LXEH Other Consumer Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- SCYX Health Care
- Exchange
- LXEH Nasdaq
- SCYX Nasdaq
- Market Cap
- LXEH 25.1M
- SCYX 28.5M
- IPO Year
- LXEH 2020
- SCYX 2014
- Fundamental
- Price
- LXEH $1.45
- SCYX $0.72
- Analyst Decision
- LXEH
- SCYX
- Analyst Count
- LXEH 0
- SCYX 0
- Target Price
- LXEH N/A
- SCYX N/A
- AVG Volume (30 Days)
- LXEH 349.7K
- SCYX 199.9K
- Earning Date
- LXEH 09-15-2025
- SCYX 08-07-2025
- Dividend Yield
- LXEH N/A
- SCYX N/A
- EPS Growth
- LXEH N/A
- SCYX N/A
- EPS
- LXEH N/A
- SCYX N/A
- Revenue
- LXEH $4,493,795.00
- SCYX $2,630,000.00
- Revenue This Year
- LXEH N/A
- SCYX $410.22
- Revenue Next Year
- LXEH N/A
- SCYX $248.83
- P/E Ratio
- LXEH N/A
- SCYX N/A
- Revenue Growth
- LXEH N/A
- SCYX N/A
- 52 Week Low
- LXEH $1.20
- SCYX $0.66
- 52 Week High
- LXEH $50.08
- SCYX $2.28
- Technical
- Relative Strength Index (RSI)
- LXEH 39.58
- SCYX 46.77
- Support Level
- LXEH $1.32
- SCYX $0.67
- Resistance Level
- LXEH $1.54
- SCYX $0.83
- Average True Range (ATR)
- LXEH 0.16
- SCYX 0.05
- MACD
- LXEH 0.09
- SCYX 0.01
- Stochastic Oscillator
- LXEH 48.18
- SCYX 46.35
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.